Genomics is on the brink of revolutionizing healthcare with breakthroughs that could redefine treatment and diagnosis. As ...

The FDA okays AstraZeneca's Fasenra for treating adults with eosinophilic granulomatosis with polyangiitis. This is the ...

We recently published a list of Jim Cramer’s Must-Watch List: 10 Stocks to Look After. In this article, we are going to take ...

Following Priority Review, Dupixent is now available to patients as young as 12 ... 13, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the FDA ...

Eli Lilly and Co.’s Ebglyss (lebrikizumab) becomes the latest U.S. entrant in the increasingly competitive atopic dermatitis space, following FDA approval of the IL-13-targeting antibody, which will ...

REGN gets FDA nod for Dupixent for a broader population for the indication of chronic rhinosinusitis with nasal polyps.

Sen. JD Vance (R-Ohio), the Republican vice presidential candidate, is backtracking on whether President Trump would veto a ...

The safety profile of Dupixent in adolescents with moderate-to-severe asthma contributed to the FDA's decision.

Eczema has multiple treatments available, including AbbVie's Rinvoq, Pfizer's Cibinqo, Sanofi and Regeneron's Dupixent as ...

Eczema, also known as atopic dermatitis, is an inflammatory skin condition that can cause itching, rashes and dry patches.

Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNPCurrent treatment ...

Regeneron Pharmaceuticals and Sanofi have received Food and Drug Administration approval for their treatment of an inflammatory condition that affects the sinuses and nasal passages in adolescents, ...